Pasithea Therapeutics (KTTA) Stock: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.53
-0.01 (-1.85%)
âŧ
5d:
-8.68%
30d:
+8.16%
90d:
-12.83%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KTTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KTTA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.53, which is considered fair relative to its 30-day fair value range of $0.47 to $0.57.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is currently testing key support at $0.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KTTA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+466.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is currently testing key support at $0.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KTTA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+466.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.47 -
$0.57
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 466.0% below Wall St target ($3.00)
- WARNING: Composite score 30/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.47 -
$0.57
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.52
Resistance Level
$0.60
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.15
Wall Street Target
$3.00
(+466.0%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: September 12, 2026 12:47 AM ET
Data refreshes hourly during market hours. Next update: 1:47 AM
Data refreshes hourly during market hours. Next update: 1:47 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
